Background: Epidemiological studies report evidence for an association between folate, an essential B vitamin, and the risk of several common cancers. However, both protective and harmful effects have been reported, and effects may differ by cancer site. These associations suggest that modulating dietary folate, or its synthetic form folic acid, could be used to modify population-wide cancer risk. However, observational studies are liable to biases, including residual confounding and reverse causation, thus limiting causal inference. Using Mendelian randomisation (MR), we investigated the causal relationships of genetically determined serum folate with pan-cancer risk (all cancers excluding non-melanoma skin cancers); breast, prostate, ovarian, lung, and colorectal cancers; and malignant melanoma.
Introduction 1
Folate is an essential B vitamin found in foods such as dark leafy green vegetables, liver and legumes. Serum 2 folate reflects recent folate intake and is the earliest biomarker to detect folate status [1] . Folic acid, the 3 synthetic form of folate, is available as a dietary supplement and is used to fortify food such as bread flour in 4 over 80 countries worldwide [2] . At the time of writing, many European countries, including the UK have yet 5 to decide or have rejected a mandate of folic acid fortification, with some countries opting for a voluntary 6 scheme or no population-wide intervention at all [2] . Recently, the UK government has released a report 7 conducted by the Scientific Advisory Committee on Nutrition (SACN) [3] and proposed a public consultation on 8 the mandatory fortification of flour with folic acid. Decisions by governments regarding this public health 9
intervention are made based on all evidence of adverse effects including any potential cancer risk. 10
Folate has an essential role in the synthesis and methylation of DNA and is a crucial co-factor in one-carbon 11 metabolism together with other B vitamins such as vitamins B2, B6, and B12 [4] . In developing foetuses, 12 insufficient folate increases the risk of neural tube defects, including spina bifida and anencephaly [5, 6] . In 13 adults, insufficient folate can lead to anaemia [7] . There is also a suggestion that low folate may contribute to 14 carcinogenesis through aberrations in DNA methylation and uracil misincorporation, leading to DNA 15 instability [8] . Folic acid supplementation was shown to have tumour-promoting effects in mouse models [9] . 16
Epidemiological studies exploring associations of folate with the risk of developing site-specific cancers have 17 been inconsistent. For instance, total folate, dietary folate and serum folate levels have been reported to have 18 no associations with breast cancer [10, 11] , whilst in contrast, a meta-analysis of 26 case-control studies reports 19 protective effects of higher dietary folate intake [12] . Likewise, some meta-analyses suggest positive 20 associations between serum folate and prostate cancer [13] , while others suggest no evidence of associations 21 with folate intake [14, 15] . These inconsistencies are also present for studies examining folate and colorectal 22 cancer [16, 17] . Much of the observational studies to date are limited due to small study sample sizes, 23 measurement error, heterogeneity of the exposure measurement (dietary intake vs. supplement intake vs. 24 circulating levels), timing of folate measurement (leading to possible reverse causation), and the use of data 25 from both pre-and post-folic acid fortification study populations [18] . 26
Several randomised control trials (RCTs) have been conducted exploring the effects of folic acid 27 supplementation on a range of primary outcomes while having also recorded incident cancers. A 2013 pooled 28 analysis of such RCTs compared folic acid supplementation and placebo for the incidence of cancers during 29 treatment periods. The primary outcome of interest was overall cancer, with additional analyses within site-30 specific cancers. In total, 3,713 cancers were reported in around 50,000 participants with a weighted average 31 treatment period of 5. individuals of European ancestry were identified as potential instruments. We excluded rs12085006 and 63 rs7554327 as they are in near-perfect linkage disequilibrium (LD) with rs1999594 (R 2 1.00) and rs7545014 (R 2 64 0.99) respectively. Detailed information on the selected genetic instruments is provided in Table 1 . 65
Data on the genetic epidemiology of cancers 66
We retrieved summary statistics of the genetic effects for the selected instruments on the risk of site-specific 67 cancers from large, recently published GWAS. Supplementary Table S1 . We also performed GWAS for pan-cancer in UKBB using data 84 for all cancer sites (ICD9:140.0-208.9 and ICD10:C00-C97 specific codes with the exclusion of ICD10:C44.0-85 C44.9; ICD9:173.0-173.9 non-melanoma skin cancers). Further details on the definition of cases and controls, 86 quality control, imputation, GWAS and statistical analysis can be found in the Supplementary Methods and 87 Supplementary Table S1 . All three instruments for serum folate were available in each of the GWAS consortia 88 and in UKBB. 89
Mendelian randomisation analysis 90
We conducted two-sample MR analyses to appraise the potential causality of associations between serum 91
folate and the risk of pan-cancer and six site-specific cancers (breast, prostate, ovarian, colorectal, lung and 92 malignant melanoma) [34] . 93
The beta-coefficients for the associations of each SNP with serum folate levels were reported on the Log10 94 scale. These were converted to the standard deviation (SD) scale to represent an SD change in log10 95 transformed serum folate with each additional effect allele (see supplementary material). We harmonised the 96
SNPs so that the effect alleles were the serum folate increasing alleles. 97
The three SNPs are located within a 100kb region around the MTHFR gene on chromosome 1 and are in weak 98 LD with each other (all R 2 <0.45) (see Supplementary Table S2 ). The use of multiple correlated SNPs (such as 99 these) introduces bias in the precision of the overall causal effect estimates. To mitigate this bias of over 100 precision, we used extensions of the fixed-effect inverse variance weighted (IVW) method and the likelihood-101 based approach to account for the correlation structure between the SNPs using a matrix of SNP 102 correlations [35, 36] . A matrix of correlations was constructed using the TwoSampleMR R package, which uses 103 reference data on participants of European ancestry within the 1000 Genomes project (Phase 3) [37] . 104
Fixed-effects IVW meta-analysis was performed to pool the MR estimates from the GWAS consortia studies 105
and UKBB for the following cancers: breast, prostate, ovarian, colorectal and lung. Cochran's Q statistic was 106 used to assess heterogeneity between studies. 107
Sensitivity analyses 108
The validity of the effect estimates and interpretation in MR analyses are reliant on the following 109 assumptions[38]: i) the selected genetic instruments are robustly associated with serum folate; ii) the genetic 110 instruments affect cancer only through their effect on serum folate; and iii) the instruments are independent 111 of any confounders of the association between serum folate and cancer. 112
To evaluate the first MR assumption, we estimated the variance in serum folate explained (R 2 ) by each SNP as 113 well as the strength of the instruments represented by the F-statistic. The R 2 and the F-statistic can be used to 114 evaluate the strength of our instruments and to indicate weak instrument bias [39] . Derivation of the R 2 and 115 the F-statistic is given in the Supplementary methods. To evaluate potential violation of the second and third 116 assumption, we performed look-ups for each of our instruments using the MR-Base PheWAS 117
(http://phewas.mrbase.org/) tool to determine the presence of associations with secondary phenotypes that 118 could be potential confounders of the association. Due to the limited number of folate SNPs, and their 119 correlation, we were unable to assess potential violations of the second assumption of MR (no horizontal 120 pleiotropy) using statistical methods (MR-Egger, weighted median and mode estimators). 121
Cochran's Q statistic was calculated to assess heterogeneity across SNPs in the causal estimate, with the null 122 hypothesis being that such differences between individual-SNP effect sizes are due to chance [40] . Where there 123 was evidence of heterogeneity (P-value <0.05), a (multiplicative) random-effects IVW and maximum likelihood 124 MR analysis[41] was performed, accounting for the correlation between SNPs. 125
To further elucidate the potential impact of using correlated SNPs as an instrument we derived the magnitude 126
to which increasing folate might affect the risk of cancer by calculating the ratio of coefficients (Wald 127 ratios) [42] for each SNP individually. The corresponding SEs were derived using the delta method [43] . In 128 addition, we explored systematically whether an individual SNP was driving the main MR association results 129 by performing a leave-one-out analysis, whereby IVW estimates are derived iteratively by excluding each SNP 130 in turn. 131
Statistical power 132
Power calculations were performed using the online tool mRnd (http://cnsgenomics.com/shiny/mRnd/) as 133 described previously [44] . The statistical power to detect a range of odds ratios (ORs) (1.05, 1.1, 1.2, 1.3, 1.4, 134 and 1.5 or their respective inverse) per SD change in log10 serum folate levels given the sample size in each 135 cancer GWAS, a type 1 error of 5%, and a total variance explained by the instruments of 5% (see below), are 136
given in Supplementary Table S3 . 137
The number of cancer cases ranged from 1,277 for ovarian cancer in UKBB to 122,977 for breast cancer in 138 BCAC. We had >80% power to detect modest effect sizes (OR 1.1 or its inverse 0.9) in our MR analysis for 139 consortia studies of cancer of the breast (BCAC), prostate (PRACTICAL), and colorectum (GECCO-CORECT-140 CCFR) cancers as well as pan-cancers from UKBB. We had a lower power to detect an OR of 1.1 for the consortia 141 studies of ovarian (OCAC, 77%) and lung (ILCCO, 42%) cancers. For UKBB, where cases were not enriched 142 within the dataset, power to detect an OR of 1.1 ranged from 13% to 100%. Supplementary Table S3 
Mendelian randomisation estimates for the association between serum folate and cancer 153
Our Mendelian randomisation effect estimates showed consistent inverse relationships for all cancer 154 outcomes (except colorectal cancer) using both the IVW method and the likelihood-based approach. As effect 155 estimates were very similar between the IVW method and the likelihood-based approach, all subsequent 156 analyses utilise the IVW estimates. Together, the MR effect estimates confer a possible protective effect of 157 increasing serum folate on the risk of cancers. In contrast, the colorectal cancer causal estimates suggest 158 increasing risk with increasing serum folate. These results were concordant between those of the consortia 159 studies and UKBB. However, our estimates are imprecise with 95% confidence intervals crossing the null 160
suggesting that there was little evidence of causal associations (Table 2) . 161
Overall, there was little evidence of heterogeneity using the Cochran's Q statistic between effect estimates 162 for each of the three serum folate SNPs (P-value for heterogeneity >0.1) in our MR analyses. This is with the 163 exception of breast cancer in UKBB (P-value for heterogeneity 0.03) and colorectal cancer in GECCO-CORECT-164 CCFR (P-value for heterogeneity 0.002) ( Table 2) . Random effects IVW and likelihood approach is reported for 165 these two cancers. Supplementary Figure S1 show scatter plots of associations between serum folate SNPs 166 and the risk of each of the cancer studies analysed. Results for individual single SNP MR analysis (using Wald 167 ratios) are provided in Supplementary Table S4 . There no strong evidence for causal associations between any 168 of the individual SNPs and cancer. Overall, effect estimates were concordant with that of the IVW MR analysis. 169 Figure 1 shows a forest plot depicting our MR causal estimates for each cancer study as well as the pooled 170 effects using fixed-effects IVW meta-analysis for breast, prostate, ovarian, lung and colorectal cancer. Pooled 171 estimates were concordant in magnitude and direction of effect to those of the individual studies, conferring 172 a protective effect on the risk of cancer with increasing serum folate. Again, there was little evidence of causal 173 associations with confidence intervals crossing the null. In addition, there was little evidence of heterogeneity 174 between the studies in each meta-analysis (P-value for heterogeneity >0.6). Supplementary Table S5 gives 175 meta-analysis causal estimates and between-study heterogeneity results. 176
Sensitivity analyses and evaluation of Mendelian randomisation assumptions 177
After look-up within the MR-Base PheWAS database, we found some evidence from GWAS that the three SNPs 178
were associated with additional phenotypes at genome-wide significance (P-value <1x10 -5 ) ( Supplementary  179  Table S6 ). All three SNPs were associated with blood cell traits; rs1801133 is associated with mean corpuscular 180 haemoglobin, mean corpuscular volume, plateletcrit (a measure of total platelet mass), and red cell 181 distribution width [46] . Whilst rs7545014 and rs1999594 are associated with plateletcrit and platelet 182 count [46] . In addition, rs1801133 is associated with several vascular phenotypes including diastolic blood 183 pressure and hypertension in UKBB as well as birthweight of first child and hip circumference. Rs1999594 is 184
additionally associated with diastolic blood pressure and rs7545014 is associated with the operative procedure 185 to excise umbilicus; both within UKBB. 186
Leave-one-out analysis suggests that it is unlikely that any individual SNP was driving the IVW MR results we 187 report as shown by the forest plot illustrated in Supplementary Figure S2 . 
Pan-cancer 272
Most studies published to date have focused on site-specific cancers. In this study, we have performed a 273 genome-wide association analysis for pan-cancers. This allowed us to appraise the impact of folate on cancer 274 risk across all sites in the general population. Proposed mechanisms for the formation of cancer via folate 275 stems from the effects of perturbation of the one-carbon metabolism pathway effects of methylation and 276 DNA repair and synthesis mechanisms which are common to the pathogenesis of many cancers [57] . However, 277
we found little evidence of causal associations with pan-cancer, although the effect estimates were protective 278 and of similar magnitude to those of the site-specific cancers. Likewise, a recent pooled analysis of RCTs 279
showed that folic acid supplements had little effect on the risk of total cancer incidence (RR 1.06; 95% CI 0.99-280
1.13) [19] . The number of cancer cases was modest (3,713 cases) and the mean follow-up time for included 281 studies was five years, limiting conclusions of long-term impacts of folic acid supplementation. 282
In cancer treatment, antifolates are key compounds which inhibit enzymes in the folate metabolic pathway 283 disrupting tumour growth and progression [58] . Due to the high proliferation of cells and demand for DNA, 284
increasing levels of folate may promote the growth of precursor or established tumours in animal 285 models [18, 59] . Conversely, in normal tissues, insufficient folate levels may impair DNA replication and repair, 286
providing possible mechanisms for the initiation of cancer through gene mutation and chromosomal 287 aberrations. Indeed, administration of folate has shown to reverse these effects [60] . This may support the 288 general findings of protective effect estimates as reported for the multiple cancers within this MR study and 289
in previously published studies. The role of folate in cancer treatment strategies, as well as the proposed 290 mechanisms for carcinogenesis and progression, suggests that potential associations between folate and 291 cancer may not be in terms of risk per se, but rather in progression and survival. 292
Folate intake has been reported to have a protective effect in cancers at sites not included in this current 293 study, including oral cavity and pharyngeal cancer, bladder, oesophageal, and pancreatic cancer [18] . Further 294 work is needed to establish extensive well-powered publicly available GWAS data in order to elucidate the 295 causal effects on these cancers, which is outside the scope of this current study. 296
Strengths and limitations 297
This study's major strength is the use of two-sample MR, which is less prone to biases from confounding, 298 reverse causation and measurement error that is seen in observational studies using directly measured 299
phenotypes. Observational studies have tended to focus on dietary and/or supplement intake of folic acid 300 using methods such as food frequency questionnaire and diet diaries. These methods have inherent limitations 301 such as recall bias and insufficient food composition tables leading to measurement error. Although a genetic 302 proxy of an exposure provides a more objective means with which to asses a causal relationship; measurement 303 error such as that described above can bias the casual estimates. In our study, we used genetic proxies for 304 serum folate level. Circulating biomarkers provide a more proximal measure of nutrition status and is more 305 objectively measured [61] . 306
Several important factors should ideally be met for instruments to be considered robust. One factor is that 307
variants have a biologically plausible relationship to the exposure (though this is not mandatory), i.e. located 308 at or near genes with established pathways relevant to the exposure. Further strengths were the ability to additionally perform GWAS in the UKBB enabling a comparison of 317 population cohort effect estimates with those of case ascertained consortia studies and ultimately allowing 318 meta-analysis, further increasing statistical power to detect modest effect estimates. 319
We also have several limitations that impact our interpretation of findings. We were unable to extend our 320 analysis to allow for stratified analyses by factors of interest such as alcohol intake, BMI, sex, age, menopausal 321 status and smoking. Our causal estimators assumed a linear relationship, and we were also unable to test for 322 deviations from this. Several methods have recently been developed to explore non-linear relationships 323 within an MR framework; however, these approaches are underpowered and require access to individual-324 level data [63] . 325
We had greater than 90% power to detect our reported MR ORs for breast, prostate, ovarian, lung and 326 colorectal cancer in the consortia GWAS meta-analysis datasets. However, we had lower power for the cancers 327 appraised using UKBB. Where possible, we performed meta-analysis within each site-specific cancer; which 328 increases statistical power; but we may still be underpowered to detect clinically relevant but smaller 329 magnitude effects. Furthermore, statistical power in MR is dependant on the amount of variance in the 330 exposure variable explained by the genetic variants. The three SNPs within our MR were in weak LD with each 331 other; therefore, it is likely that the variance explained is lower than that of the sum of the three SNPs (R 2 5%). 332
Further work to identify additional SNPs robustly associated with serum folate in larger GWAS and meta-333 analysis will go some way to improving statistical power. 334
The SNPs included in our instrument were found to be associated with vascular traits, and cell and platelet 335 measures in MR-Base PheWAS. Grarup The funders played no role in the design, implementation, analysis, or interpretation of the data in this study. 367 The odds ratios (OR) were derived using the inverse variance weighted method and correspond to a 1 SD increase in log10 397 serum folate levels. Meta -IVW correspond to the fixed effects IVW meta-analysis results; * there will be over precision 
